NewLink Genetics Corporation (NASDAQ:NLNK) Lifted to “Hold” at Zacks Investment Research

NewLink Genetics Corporation (NASDAQ:NLNK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Saturday, July 29th.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Several other equities analysts also recently weighed in on NLNK. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research report on Thursday, April 6th. Jefferies Group LLC lifted their target price on NewLink Genetics Corporation from $15.00 to $18.00 and gave the company a “hold” rating in a research report on Thursday, April 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $32.00 target price (up from $20.00) on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. ValuEngine raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Finally, Robert W. Baird reissued an “outperform” rating and set a $25.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $18.17.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 6.35 on Friday. The stock has a 50 day moving average of $7.17 and a 200-day moving average of $13.39. The company’s market capitalization is $186.82 million. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. Equities analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “NewLink Genetics Corporation (NASDAQ:NLNK) Lifted to “Hold” at Zacks Investment Research” was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/zacks-investment-research-upgrades-newlink-genetics-corporation-nasdaqnlnk-to-hold-updated-updated.html.

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company increased its position in shares of NewLink Genetics Corporation by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the period. State Street Corp increased its position in shares of NewLink Genetics Corporation by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of NewLink Genetics Corporation during the second quarter worth about $286,000. PDT Partners LLC increased its position in shares of NewLink Genetics Corporation by 160.2% in the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after buying an additional 71,295 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of NewLink Genetics Corporation by 40.2% in the second quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock worth $888,000 after buying an additional 34,624 shares during the period. 51.42% of the stock is owned by hedge funds and other institutional investors.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply